Results 141 to 150 of about 3,780 (219)
POTENTIAL FOR ABUSE OF ANTIPARKINSON AGENTS
Psychiatric Services, 1982 Hospital &‘ Community Psychiatrj is expanding its roster of peer reviewers for manuscripts submitted for publication. Professionals in the mental health disciplines who are qualified to serve as peer reviewers are invited to contact the editor. Reviewers must have significant publications in their specialty area, be abreast of the liteEature in that ...
James M. Smith, Winston W. Shen
openalex +3 more sources
Carotenoids as Antiparkinson Agents
, 2021 Parkinson’s disease (PD) is a neurodegenerative disease associated with the loss of dopaminergic neurons in the portions of the brain via multiple pathological mechanisms. Despite the fact that enormous progress occurred in the cure of Parkinson’s disorder, but the incidence and risk of this disease is increasing alarmingly over the past few decades ...
Saikat Dewanjee +5 more
openalex +2 more sources
New L‐Dopa Codrugs as Potential Antiparkinson Agents
Archiv der Pharmazie, 2008 AbstractThis paper reports the synthesis and preliminary evaluation of newL‐dopa (LD) conjugates (1and2) obtained by joining LD with two different natural antioxidants, caffeic acid and carnosine, respectively. The antioxidant efficacy of compounds1and2was assessed by evaluating plasmatic activities of superoxide dismutase (SOD) and glutathione ...
Piera Sozio +9 more
openalex +5 more sources
[Immunotropic activity of a potential antiparkinson agent himantane].
Eksperimental'naia i klinicheskaia farmakologiia, 2001 N-(Adamant-2-yl) hexamethyleneimine hydrochloride (A-7, himantane), a new potential antiparkinsonian drug belonging to the class of aminoadamantyl derivatives, exhibits pronounced immunomodulant activity in a therapeutic dose of 10 mg/kg. A single intraperitoneal injection of himantane stimulated a high B-lymphocyte activity in mice over a period of 21
G I Nezhinskaia +3 more
openalex +3 more sources
Efficacy of antiparkinson agents in preventing antipsychotic-induced extrapyramidal symptoms
American Journal of Health-System Pharmacy, 1979 The types of extrapyramidal syndrome (EPS) reactions produced by antipsychotic agents and the prophylactic use of antiparkinson agents in preventing EPS are reviewed. EPS are classified as akathisias, dystonias, parkinson-like symptoms and tardive dyskinesia, and have a varied incidence reported to range from 10.6 to 100%.
John E. Murphy, Ronald B. Stewart
openalex +3 more sources
[Phenibut potentiation of the therapeutic action of antiparkinson agents].
Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1986 It was observed in experiments on mice that the central action of phenibut (beta-phenyl-gamma-aminobutyric acid) diminished after destruction of brain dopaminergic neurons by 6-hydroxydopamine and after pretreatment with the dopamine receptor blocker haloperidol which suggests the dopaminergic component in the action of phenibut.
Iu V Gol'dblat, I. P. Lapin
openalex +3 more sources
Withdrawal from long-term use of antiparkinson agents taken with antipsychotic agents
International Clinical Psychopharmacology, 1998 Minako Koga +4 more
openalex +2 more sources